Anbio Biotechnology Class A Ordinary Shares (NNNN) 10-Year Financial Performance & Capital Metrics

NNNN • • Industrial / General

HealthcareMedical InstrumentsDiagnostic & Monitoring EquipmentDiagnostic Testing & Monitoring

AboutAnbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.Show more

Revenue $8M +21.9%
EBITDA $3M +30.0%
Net Income $2M +5.3%
EPS (Diluted) 0.06 +366.7%
Gross Margin 71.9% +43.6%
EBITDA Margin 31.36% +6.6%
Operating Margin 24.38% -16.6%
Net Margin 28.99% -13.7%
ROE 14.83% -10.0%
ROIC 28.34% +1.9%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 54.7%
✓FCF machine: 25.4% free cash flow margin
✓Momentum leader: RS Rating 94 (top 6%)
✓Share count reduced 77.5% through buybacks
✓Healthy 5Y average net margin of 40.6%

✗Weaknesses

✗Trading more than 30% below 52-week high
✗Expensive at 85.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y22.72%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-2.19%

TTM-

EPS CAGR

10Y-

5Y-

3Y30.15%

TTM-

ROCE

10Y Avg64.71%

5Y Avg64.71%

3Y Avg54%

Latest12.47%

Peer Comparison

Diagnostic Testing & Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NNNNAnbio Biotechnology Class A Ordinary Shares	1.52B	34.59	617.68	21.95%	31.03%	29.08%	0.14%
DXRDaxor Corporation	69.03M	13.70	124.55	-93.84%	401.5%	9.78%	0.04%	0.02
BDXBecton, Dickinson and Company	59.36B	208.35	35.74	8.23%	7.68%	6.61%	4.5%	0.76
HOLXHologic, Inc.	16.73B	75.02	22.60	-0%	13.79%	11.5%	6.84%	0.52
GCTKGlucoTrack, Inc.	3.62M	3.98	0.07			-389.1%
QDELQuidelOrtho Corporation	2.4B	35.38	-1.16	-7.17%	-43.43%	-57.92%		0.90
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.	1.34B	22.98	-4.48	115.05%	-177.99%	-80.55%		0.22
OSUROraSure Technologies, Inc.	196.55M	2.74	-10.54	-54.17%	-47.92%	-16.64%	12%	0.04

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.43M	23.54M	6.71M	8.19M
Revenue Growth %	-	4.32%	-0.71%	0.22%
Cost of Goods Sold+	1.89M	10.98M	3.35M	2.3M
COGS % of Revenue	0.43%	0.47%	0.5%	0.28%
Gross Profit+	2.54M	12.56M	3.36M	5.89M
Gross Margin %	0.57%	0.53%	0.5%	0.72%
Gross Profit Growth %	-	3.94%	-0.73%	0.75%
Operating Expenses+	86.09K	2.37M	1.4M	3.89M
OpEx % of Revenue	0.02%	0.1%	0.21%	0.48%
Selling, General & Admin	86.09K	2.17M	1.27M	3.44M
SG&A % of Revenue	0.02%	0.09%	0.19%	0.42%
Research & Development	0	200K	134.7K	454.23K
R&D % of Revenue	-	0.01%	0.02%	0.06%
Other Operating Expenses	0	0	0	0
Operating Income+	2.46M	10.2M	1.96M	2M
Operating Margin %	0.55%	0.43%	0.29%	0.24%
Operating Income Growth %	-	3.15%	-0.81%	0.02%
EBITDA+	2.54M	10.2M	1.97M	2.57M
EBITDA Margin %	0.57%	0.43%	0.29%	0.31%
EBITDA Growth %	-	3.02%	-0.81%	0.3%
D&A (Non-Cash Add-back)	0	6.25K	13.04K	0
EBIT	2.54M	10.02M	2.25M	2.37M
Net Interest Income+	0	34.25K	165.34K	337.51K
Interest Income	0	42.24K	165.34K	337.51K
Interest Expense	0	8K	0	0
Other Income/Expense	79.94K	-184.41K	292.78K	377.48K
Pretax Income+	2.54M	10.01M	2.25M	2.37M
Pretax Margin %	0.57%	0.43%	0.34%	0.29%
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	2.54M	10.01M	2.25M	2.37M
Net Margin %	0.57%	0.43%	0.34%	0.29%
Net Income Growth %	-	2.95%	-0.77%	0.05%
Net Income (Continuing)	2.54M	10.01M	2.25M	2.37M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	0.03	0.07	0.01	0.06
EPS Growth %	-	1.74%	-0.83%	3.67%
EPS (Basic)	0.03	0.07	0.02	0.06
Diluted Shares Outstanding	100M	143.89M	187.78M	42.29M
Basic Shares Outstanding	100M	143.89M	143.89M	42.29M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.92M	13.94M	15.75M	18.53M
Cash & Short-Term Investments	4.18M	8.67M	9.69M	11.76M
Cash Only	4.18M	7.1M	9.69M	11.76M
Short-Term Investments	0	1.57M	0	0
Accounts Receivable	717.5K	3.58K	1.88M	1.06M
Days Sales Outstanding	59.14	0.06	102.5	47.48
Inventory	0	353.87K	0	0
Days Inventory Outstanding	-	11.76	-	-
Other Current Assets	0	0	0	0
Total Non-Current Assets+	0	15.05K	62.14K	387.44K
Property, Plant & Equipment	0	12.06K	0	0
Fixed Asset Turnover	-	1952.45x	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	2.99K	62.14K	387.44K
Total Assets+	4.92M	13.96M	15.81M	18.92M
Asset Turnover	0.90x	1.69x	0.42x	0.43x
Asset Growth %	-	1.84%	0.13%	0.2%
Total Current Liabilities+	2.38M	1.41M	993.06K	1.73M
Accounts Payable	1.89M	1.41M	827.15K	1.63M
Days Payables Outstanding	365.65	46.8	90.09	257.95
Short-Term Debt	0	0	0	0
Deferred Revenue (Current)	490K	0	0	0
Other Current Liabilities	0	0	0	0
Current Ratio	2.07x	9.88x	15.86x	10.71x
Quick Ratio	2.07x	9.63x	15.86x	10.71x
Cash Conversion Cycle	-	-34.98	-	-
Total Non-Current Liabilities+	0	0	0	0
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	0
Total Liabilities	2.38M	1.41M	993.06K	1.73M
Total Debt+	0	0	0	0
Net Debt	-4.18M	-7.1M	-9.69M	-11.76M
Debt / Equity	-	-	-	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-1.65x	-0.70x	-4.91x	-4.58x
Interest Coverage	-	1274.61x	-	-
Total Equity+	2.54M	12.55M	14.82M	17.19M
Equity Growth %	-	3.95%	0.18%	0.16%
Book Value per Share	0.03	0.09	0.08	0.41
Total Shareholders' Equity	2.54M	12.55M	14.82M	17.19M
Common Stock	0	0	14.23K	14.23K
Retained Earnings	2.54M	12.55M	14.8M	17.17M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	4.18M	4.45M	898.37K	2.08M
Operating CF Margin %	0.94%	0.19%	0.13%	0.25%
Operating CF Growth %	-	0.06%	-0.8%	1.32%
Net Income	2.54M	10.01M	2.25M	2.37M
Depreciation & Amortization	0	6.25K	12.06K	0
Stock-Based Compensation	0	0	0	0
Deferred Taxes	0	0	0	0
Other Non-Cash Items	0	-40.87K	-163.39K	-337.1K
Working Capital Changes	1.65M	-5.53M	-1.2M	44.65K
Change in Receivables	-717.5K	717.5K	-1.88M	820.17K
Change in Inventory	0	-353.87K	353.87K	0
Change in Payables	1.89M	-481.82K	-580.89K	798.1K
Cash from Investing+	0	-1.53M	1.73M	337.1K
Capital Expenditures	0	0	0	0
CapEx % of Revenue	-	0%	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	0	0	-42.84K	-344.61K
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	0	-42.84K	-344.61K
Net Change in Cash	-	-	-	-
Free Cash Flow+	4.18M	4.45M	898.37K	2.08M
FCF Margin %	0.94%	0.19%	0.13%	0.25%
FCF Growth %	-	0.06%	-0.8%	1.32%
FCF per Share	0.04	0.03	0.00	0.05
FCF Conversion (FCF/Net Income)	1.65x	0.44x	0.40x	0.88x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	100%	132.75%	16.47%	14.83%
Return on Invested Capital (ROIC)	-	402.54%	27.81%	28.34%
Gross Margin	57.4%	53.36%	50.07%	71.9%
Net Margin	57.26%	42.52%	33.58%	28.99%
Interest Coverage	-	1274.61x	-	-
FCF Conversion	1.65x	0.44x	0.40x	0.88x
Revenue Growth	-	431.67%	-71.49%	21.95%

Frequently Asked Questions

Growth & Financials

Anbio Biotechnology Class A Ordinary Shares (NNNN) reported $16.1M in revenue for fiscal year 2024. This represents a 264% increase from $4.4M in 2021.

Anbio Biotechnology Class A Ordinary Shares (NNNN) grew revenue by 21.9% over the past year. This is strong growth.

Yes, Anbio Biotechnology Class A Ordinary Shares (NNNN) is profitable, generating $5.0M in net income for fiscal year 2024 (29.0% net margin).

Dividend & Returns

Anbio Biotechnology Class A Ordinary Shares (NNNN) has a return on equity (ROE) of 14.8%. This is reasonable for most industries.

Anbio Biotechnology Class A Ordinary Shares (NNNN) generated $3.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

← Back to Screener